UTICA COLLEGE NUR 621 Final Exam
Study Guide (2026/2027): Gastrointestinal
Disorders
Table of Contents
1. Course Topic Overview
2. Multiple-Choice Questions (1–30)
3. Answer Key
4. Detailed Rationales
5. High-Yield Review Sheet
Course Topic Overview
Advanced Practice Nursing in gastroenterology requires a sophisticated understanding of
complex luminal, hepatobiliary, pancreatic, and vascular disorders across the lifespan.
Advanced Practice Nurses (APNs) must synthesize clinical findings, interpret advanced
diagnostics, and manage acute and chronic gastrointestinal (GI) pathologies using
evidence-based, patient-centered frameworks.
Definitions
● Gastroesophageal Reflux Disease (GERD): Chronic symptoms or mucosal damage
produced by the abnormal reflux of gastric contents into the esophagus.
● Inflammatory Bowel Disease (IBD): Chronic, relapsing inflammatory disorders of the
gastrointestinal tract, encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC).
● Cirrhosis: A late stage of hepatic fibrosis characterized by distortion of normal hepatic
architecture, regenerative nodules, and portal hypertension.
Pathophysiology
● Peptic Ulcer Disease (PUD): Imbalance between aggressive mucosal factors (gastric
acid, pepsin, H. pylori, NSAIDs) and defensive mucosal mechanisms (prostaglandins,
mucus, bicarbonate).
● IBD Pathogenesis: Dysregulated mucosal immune response to commensal luminal
flora in genetically susceptible hosts, leading to chronic transmural (Crohn's) or mucosal
(Ulcerative Colitis) inflammation.
, ● Portal Hypertension: Increased resistance to portal blood flow compounded by
splanchnic arteriolar vasodilation, resulting in portosystemic shunting, ascites, and
varices.
Risk Factors
● H. pylori infection, chronic NSAID or aspirin use, smoking, and psychological stress.
● Family history of IBD, autoimmune disorders, Westernized diets, and environmental
triggers.
● Chronic alcohol consumption, non-alcoholic fatty liver disease (NAFLD/MASLD), and
chronic viral hepatitis (HBV/HCV).
Clinical Manifestations
● Heartburn, dysphagia, epigastric pain, hematemesis, melena, hematochezia, and
abdominal distension.
● Systemic features: Unexplained weight loss, chronic fatigue, low-grade fevers, nocturnal
diarrhea, and extraintestinal manifestations (uveitis, arthralgia, pyoderma gangrenosum).
Assessment Findings
● Abdominal tenderness, guarding, rebound tenderness, hepatosplenomegaly, shifting
dullness, fluid wave, spider angiomas, palmar erythema, and asterixis.
● Nutritional wasting, oral aphthous ulcers, and perianal skin tags or fistulae.
Differential Diagnoses
● Functional Dyspepsia vs. PUD vs. GERD vs. Esophageal Malignancy.
● Irritable Bowel Syndrome (IBS) vs. Inflammatory Bowel Disease (IBD) vs. Ischemic
Colitis.
● Acute Cholecystitis vs. Acute Pancreatitis vs. Peptic Ulcer Perforation.
Diagnostic Testing
● Upper and lower endoscopies with targeted mucosal biopsies.
● Cross-sectional imaging (CT enterography, MR enterography, abdominal ultrasound with
Doppler).
● Serological panels (ASCA for Crohn's, p-ANCA for Ulcerative Colitis, anti-tTG for celiac
disease).
● Fecal calprotectin and stool occult blood testing.
Evidence-Based Management
● Step-up versus top-down biologic therapy for IBD management.
, ● Hepatocellular carcinoma (HCC) and variceal surveillance protocols in cirrhosis.
● Antimicrobial eradication regimens for H. pylori infection.
Pharmacological Interventions
● Proton Pump Inhibitors (PPIs) and H2-receptor antagonists for acid-peptic disease.
● Corticosteroids, immunomodulators (thiopurines, methotrexate), and biologic agents
(anti-TNF, anti-integrins, anti-IL12/23) for IBD.
● Non-selective beta-blockers (e.g., carvedilol, propranolol) for primary and secondary
prophylaxis of variceal bleeding.
● Lactulose and rifaximin for hepatic encephalopathy management.
Non-Pharmacological Interventions
● Nutritional therapy (exclusive enteral nutrition, low-FODMAP diet, sodium restriction for
ascites).
● Endoscopic therapies (variceal band ligation, stricture dilation, polypectomy).
● Surgical resection, strictureplasty, or bariatric modifications.
Patient Education
● Dietary modification and lifestyle adjustments (trigger food avoidance, smoking
cessation, weight management).
● Medication adherence and recognition of immunosuppressive therapy infection risks.
● Warning signs of GI bleeding, bowel obstruction, or peritonitis requiring immediate
intervention.
Follow-Up Care
● Surveillance colonoscopy schedules for patients with long-standing IBD or colonic
polyps.
● Biochemical liver function monitoring and imaging surveillance for cirrhotic patients.
● Nutritional status tracking and micronutrient replacement regimens.
Multiple-Choice Questions
1. A 45-year-old male presents with chronic, burning epigastric pain that worsens 2 to 3
hours after meals and is occasionally relieved by food or antacids. He reports daily use
of high-dose ibuprofen for chronic low back pain. Which underlying pathophysiological
mechanism is primarily responsible for his symptoms? A. Autoimmune destruction of
gastric parietal cells B. Inhibition of mucosal protective prostaglandins by NSAIDs C.
Hypersecretion of gastrin secondary to a neuroendocrine tumor D. Direct caustic injury
from alkaline duodenal reflux
Study Guide (2026/2027): Gastrointestinal
Disorders
Table of Contents
1. Course Topic Overview
2. Multiple-Choice Questions (1–30)
3. Answer Key
4. Detailed Rationales
5. High-Yield Review Sheet
Course Topic Overview
Advanced Practice Nursing in gastroenterology requires a sophisticated understanding of
complex luminal, hepatobiliary, pancreatic, and vascular disorders across the lifespan.
Advanced Practice Nurses (APNs) must synthesize clinical findings, interpret advanced
diagnostics, and manage acute and chronic gastrointestinal (GI) pathologies using
evidence-based, patient-centered frameworks.
Definitions
● Gastroesophageal Reflux Disease (GERD): Chronic symptoms or mucosal damage
produced by the abnormal reflux of gastric contents into the esophagus.
● Inflammatory Bowel Disease (IBD): Chronic, relapsing inflammatory disorders of the
gastrointestinal tract, encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC).
● Cirrhosis: A late stage of hepatic fibrosis characterized by distortion of normal hepatic
architecture, regenerative nodules, and portal hypertension.
Pathophysiology
● Peptic Ulcer Disease (PUD): Imbalance between aggressive mucosal factors (gastric
acid, pepsin, H. pylori, NSAIDs) and defensive mucosal mechanisms (prostaglandins,
mucus, bicarbonate).
● IBD Pathogenesis: Dysregulated mucosal immune response to commensal luminal
flora in genetically susceptible hosts, leading to chronic transmural (Crohn's) or mucosal
(Ulcerative Colitis) inflammation.
, ● Portal Hypertension: Increased resistance to portal blood flow compounded by
splanchnic arteriolar vasodilation, resulting in portosystemic shunting, ascites, and
varices.
Risk Factors
● H. pylori infection, chronic NSAID or aspirin use, smoking, and psychological stress.
● Family history of IBD, autoimmune disorders, Westernized diets, and environmental
triggers.
● Chronic alcohol consumption, non-alcoholic fatty liver disease (NAFLD/MASLD), and
chronic viral hepatitis (HBV/HCV).
Clinical Manifestations
● Heartburn, dysphagia, epigastric pain, hematemesis, melena, hematochezia, and
abdominal distension.
● Systemic features: Unexplained weight loss, chronic fatigue, low-grade fevers, nocturnal
diarrhea, and extraintestinal manifestations (uveitis, arthralgia, pyoderma gangrenosum).
Assessment Findings
● Abdominal tenderness, guarding, rebound tenderness, hepatosplenomegaly, shifting
dullness, fluid wave, spider angiomas, palmar erythema, and asterixis.
● Nutritional wasting, oral aphthous ulcers, and perianal skin tags or fistulae.
Differential Diagnoses
● Functional Dyspepsia vs. PUD vs. GERD vs. Esophageal Malignancy.
● Irritable Bowel Syndrome (IBS) vs. Inflammatory Bowel Disease (IBD) vs. Ischemic
Colitis.
● Acute Cholecystitis vs. Acute Pancreatitis vs. Peptic Ulcer Perforation.
Diagnostic Testing
● Upper and lower endoscopies with targeted mucosal biopsies.
● Cross-sectional imaging (CT enterography, MR enterography, abdominal ultrasound with
Doppler).
● Serological panels (ASCA for Crohn's, p-ANCA for Ulcerative Colitis, anti-tTG for celiac
disease).
● Fecal calprotectin and stool occult blood testing.
Evidence-Based Management
● Step-up versus top-down biologic therapy for IBD management.
, ● Hepatocellular carcinoma (HCC) and variceal surveillance protocols in cirrhosis.
● Antimicrobial eradication regimens for H. pylori infection.
Pharmacological Interventions
● Proton Pump Inhibitors (PPIs) and H2-receptor antagonists for acid-peptic disease.
● Corticosteroids, immunomodulators (thiopurines, methotrexate), and biologic agents
(anti-TNF, anti-integrins, anti-IL12/23) for IBD.
● Non-selective beta-blockers (e.g., carvedilol, propranolol) for primary and secondary
prophylaxis of variceal bleeding.
● Lactulose and rifaximin for hepatic encephalopathy management.
Non-Pharmacological Interventions
● Nutritional therapy (exclusive enteral nutrition, low-FODMAP diet, sodium restriction for
ascites).
● Endoscopic therapies (variceal band ligation, stricture dilation, polypectomy).
● Surgical resection, strictureplasty, or bariatric modifications.
Patient Education
● Dietary modification and lifestyle adjustments (trigger food avoidance, smoking
cessation, weight management).
● Medication adherence and recognition of immunosuppressive therapy infection risks.
● Warning signs of GI bleeding, bowel obstruction, or peritonitis requiring immediate
intervention.
Follow-Up Care
● Surveillance colonoscopy schedules for patients with long-standing IBD or colonic
polyps.
● Biochemical liver function monitoring and imaging surveillance for cirrhotic patients.
● Nutritional status tracking and micronutrient replacement regimens.
Multiple-Choice Questions
1. A 45-year-old male presents with chronic, burning epigastric pain that worsens 2 to 3
hours after meals and is occasionally relieved by food or antacids. He reports daily use
of high-dose ibuprofen for chronic low back pain. Which underlying pathophysiological
mechanism is primarily responsible for his symptoms? A. Autoimmune destruction of
gastric parietal cells B. Inhibition of mucosal protective prostaglandins by NSAIDs C.
Hypersecretion of gastrin secondary to a neuroendocrine tumor D. Direct caustic injury
from alkaline duodenal reflux
